CN102863513A - 一种醋酸去氨加压素的制备方法 - Google Patents
一种醋酸去氨加压素的制备方法 Download PDFInfo
- Publication number
- CN102863513A CN102863513A CN2012103360442A CN201210336044A CN102863513A CN 102863513 A CN102863513 A CN 102863513A CN 2012103360442 A CN2012103360442 A CN 2012103360442A CN 201210336044 A CN201210336044 A CN 201210336044A CN 102863513 A CN102863513 A CN 102863513A
- Authority
- CN
- China
- Prior art keywords
- trt
- fmoc
- gly
- arg
- resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title claims abstract description 16
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 229960002845 desmopressin acetate Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 7
- 230000008878 coupling Effects 0.000 claims abstract description 7
- 238000010168 coupling process Methods 0.000 claims abstract description 7
- 238000005859 coupling reaction Methods 0.000 claims abstract description 7
- DVBUCBXGDWWXNY-GOSISDBHSA-N (2r)-5-(diaminomethylideneazaniumyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoate Chemical group C1=CC=C2C(COC(=O)N[C@H](CCCNC(=N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-GOSISDBHSA-N 0.000 claims abstract description 4
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000001590 oxidative effect Effects 0.000 claims abstract description 4
- 238000005406 washing Methods 0.000 claims description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 10
- 239000007791 liquid phase Substances 0.000 claims description 7
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 238000005336 cracking Methods 0.000 claims description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 6
- 150000003053 piperidines Chemical class 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 claims description 3
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 claims description 3
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 claims description 3
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 claims description 3
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 claims description 3
- AECGEIVNZGQBJT-UHFFFAOYSA-N 3-tritylsulfanylpropanoic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SCCC(=O)O)C1=CC=CC=C1 AECGEIVNZGQBJT-UHFFFAOYSA-N 0.000 claims description 3
- 239000007800 oxidant agent Substances 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000009777 vacuum freeze-drying Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 229920003180 amino resin Polymers 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000028235 central diabetes insipidus Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YNKFCNRZZPFMEX-XHPDKPNGSA-N desmopressin acetate trihydrate Chemical compound O.O.O.CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 YNKFCNRZZPFMEX-XHPDKPNGSA-N 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940028441 minirin Drugs 0.000 description 1
- 201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210336044.2A CN102863513B (zh) | 2012-09-12 | 2012-09-12 | 一种醋酸去氨加压素的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210336044.2A CN102863513B (zh) | 2012-09-12 | 2012-09-12 | 一种醋酸去氨加压素的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102863513A true CN102863513A (zh) | 2013-01-09 |
CN102863513B CN102863513B (zh) | 2014-06-25 |
Family
ID=47442668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210336044.2A Active CN102863513B (zh) | 2012-09-12 | 2012-09-12 | 一种醋酸去氨加压素的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102863513B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103992389A (zh) * | 2013-09-10 | 2014-08-20 | 杭州诺泰制药技术有限公司 | 一种固环合成去氨加压素的方法 |
CN104761619A (zh) * | 2015-01-06 | 2015-07-08 | 苏州天马医药集团天吉生物制药有限公司 | 醋酸去氨加压素的固相制备工艺 |
CN107141340A (zh) * | 2017-04-18 | 2017-09-08 | 国药集团川抗制药有限公司 | 一种醋酸特利加压素的合成方法 |
CN112062813A (zh) * | 2019-06-10 | 2020-12-11 | 翰宇药业(武汉)有限公司 | 一种去氨加压素的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011011342A1 (en) * | 2009-07-20 | 2011-01-27 | Mallinckrodt Inc. | Synthesis of desmopressin |
CN101372505B (zh) * | 2007-08-22 | 2011-03-30 | 深圳翰宇药业股份有限公司 | 一种制备醋酸去氨加压素的方法 |
CN102440968A (zh) * | 2011-12-16 | 2012-05-09 | 深圳市健元医药科技有限公司 | 一种更加稳定的ddavp多肽药物冻干粉针剂 |
-
2012
- 2012-09-12 CN CN201210336044.2A patent/CN102863513B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101372505B (zh) * | 2007-08-22 | 2011-03-30 | 深圳翰宇药业股份有限公司 | 一种制备醋酸去氨加压素的方法 |
WO2011011342A1 (en) * | 2009-07-20 | 2011-01-27 | Mallinckrodt Inc. | Synthesis of desmopressin |
CN102440968A (zh) * | 2011-12-16 | 2012-05-09 | 深圳市健元医药科技有限公司 | 一种更加稳定的ddavp多肽药物冻干粉针剂 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103992389A (zh) * | 2013-09-10 | 2014-08-20 | 杭州诺泰制药技术有限公司 | 一种固环合成去氨加压素的方法 |
CN104761619A (zh) * | 2015-01-06 | 2015-07-08 | 苏州天马医药集团天吉生物制药有限公司 | 醋酸去氨加压素的固相制备工艺 |
CN107141340A (zh) * | 2017-04-18 | 2017-09-08 | 国药集团川抗制药有限公司 | 一种醋酸特利加压素的合成方法 |
CN112062813A (zh) * | 2019-06-10 | 2020-12-11 | 翰宇药业(武汉)有限公司 | 一种去氨加压素的合成方法 |
WO2020248372A1 (zh) * | 2019-06-10 | 2020-12-17 | 翰宇药业(武汉)有限公司 | 一种去氨加压素的合成方法 |
CN112062813B (zh) * | 2019-06-10 | 2022-05-03 | 翰宇药业(武汉)有限公司 | 一种去氨加压素的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102863513B (zh) | 2014-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101693738B (zh) | 一种固相氧化环合合成特利加压素的方法 | |
CN103374054B (zh) | 一步法固相合成多肽的方法 | |
WO2017101810A1 (zh) | 一种利那洛肽的合成方法 | |
CN103102395B (zh) | 一种醋酸去氨加压素的制备方法 | |
CN102863513B (zh) | 一种醋酸去氨加压素的制备方法 | |
CN101555272A (zh) | 一种固相制备卡贝缩宫素的方法 | |
CN103333239B (zh) | 固相合成胰高血糖素 | |
US9434767B2 (en) | Method for preparing atosiban acetate | |
CN104592362A (zh) | 卡贝缩宫素的合成工艺 | |
CN101463072B (zh) | 一种八肽胆囊收缩素的制备方法 | |
CN101372505B (zh) | 一种制备醋酸去氨加压素的方法 | |
CN103992389B (zh) | 一种固环合成去氨加压素的方法 | |
CN104231051A (zh) | 一种利那洛肽的制备方法 | |
CN106167514A (zh) | 一种利那洛肽的合成和纯化方法 | |
CN102558338A (zh) | 一种合成利西拉来的方法 | |
CN102702320A (zh) | 一种制备爱啡肽的方法 | |
CN102850441A (zh) | 一种缩宫素的固相合成方法 | |
CN110746491A (zh) | 一种缩宫素的生产方法 | |
CN104628826A (zh) | 利那洛肽的制备方法 | |
CN109053863A (zh) | 一种低成本制备高纯度利那洛肽的方法 | |
CN104761619A (zh) | 醋酸去氨加压素的固相制备工艺 | |
CN103467573B (zh) | 一种卡贝缩宫素的制备方法 | |
CN101863961A (zh) | 一种奥曲肽的制备方法 | |
CN103980350B (zh) | 一种固环合成阿托西班的方法 | |
CN104262464A (zh) | 一种制备卡贝缩宫素的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160324 Address after: 224555 Jiangsu Industrial Park, Binhai Economic Development Zone, Yancheng City, Zhongshan Province, two Patentee after: YANCHENG KAILI PHARMACEUTICAL Co.,Ltd. Address before: 214261 Jiangsu city of Wuxi province Yixing Zhoutie town Peng Gan Cun Patentee before: WUXI KAILI PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of desmopressin acetate Effective date of registration: 20211216 Granted publication date: 20140625 Pledgee: Binhai Haibin Investment Development Co.,Ltd. Pledgor: YANCHENG KAILI PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980015205 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230626 Granted publication date: 20140625 Pledgee: Binhai Haibin Investment Development Co.,Ltd. Pledgor: YANCHENG KAILI PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980015205 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of Desmopressin acetate Effective date of registration: 20230627 Granted publication date: 20140625 Pledgee: Binhai Haibin Investment Development Co.,Ltd. Pledgor: YANCHENG KAILI PHARMACEUTICAL Co.,Ltd. Registration number: Y2023990000319 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231124 Granted publication date: 20140625 Pledgee: Binhai Haibin Investment Development Co.,Ltd. Pledgor: YANCHENG KAILI PHARMACEUTICAL Co.,Ltd. Registration number: Y2023990000319 |